230 likes | 354 Vues
This article delves into the complex landscape of HIV treatment options, including established antiretrovirals like AZT and newer strategies such as fixed-dose combinations. The challenges of drug resistance, side effects, and adherence are highlighted, alongside the need for more accessible monitoring. Future treatment possibilities, including immune therapies and prophylactic drugs, outline the evolving fight against HIV. Insights from regions like Henan Province emphasize the importance of training and direct observation strategies in improving treatment outcomes.
E N D
Treatments, Current & Future Jon Cohen Science Magazine
Deciphering the Alphabet Soup:HIV Treatment Options and Limitations AZT d4T ddI ddC NVP EFV IND SQV 3TC FTC T-20 RT NRTI NNRTI PI FI CD4 CCR5 VL
Covering Key Treatment Issues • Dizzying array of drugs • Drugs target different vulnerable spots • Problems w/drugs: Resistance, side effects • Adherence: Simpler dosing badly needed • Monitoring: too expensive for most • Creative strategies: STIs, prophylaxis
Know the Enemy HIV CCR5 Receptor CD4 Receptor CD4 White Blood cell
HIV’s Life Cycle: Dumbed down version CD4 White Blood Cell HIV HIV HIV HIV HIV HIV HIV HIV
HIV’s Life Cycle: Smart version HIV CD4 cell
HIV’s Life Cycle Up close • Entry • Reverse Transcription • Integration • Transcription • Assembly • Budding
U.S. FDA June 2004
The Cocktails Work Percentage of Patient-days on HAART Deaths per 100 Person-Years Frank Palella/HOPS
WHO Recommended Cocktails in Resource-Limited Settings AZT/3TC* + NVP or EFV** **Alternatives to NVP or EFV: PIs *Alternatives to AZT/3TC: d4T/3TC, ZDV/ddI and ddI/3TC OR 1 pill/2x day 1 pill/2x day 1 pill/2x day 1 pill/day 5 or 6 pills/day =
But a tangled web of serious problems—and important stories—exist Biological Financial Practical Political Technical
The Story of Henan Henan Province had 20% dropout first year, and NVP resistance in first 9 months was 20%-30%.
Biological: Resistance and side effects Financial: Lack of monitoring, training, and 2nd line Tx Practical: Pills/day Technical: Do generics = brand name? Political: Export limits per WTO, No generic 3TC in China Lessons from Henan
Future Treatment Possibilities Structured Treatment Interruptions (STI): Little evidence that it works, but might Dybul et al, JID, 2004
Future Treatment Possibilities New Targets
Future Treatment Possibilities Immune Therapies • Therapeutic vaccination • Interleukin-2 • CD4 and CD8 cell infusions
Future Treatment Possibilities Drugs as Prophylaxis: Tenofovir Study